RecruitingNot Applicable

Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist

South Korea38 participantsStarted 2023-07-13

Plain-language summary

In patients with chronic elbow or wrist pain, the pain is controlled by conventional conservative therapy The pain reduction effect of Nexsphere-F embolization in patients who need additional treatment It is intended to demonstrate safety.

Who can participate

Age range19 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Those aged 19 to 80
✓. Anyone who can provide a consent form
✓. A person with a life expectancy of at least 12 months
✓. Those who have not responded or failed in preservation treatment for at least three months(e.g. NSAIDS/physical therapy/steroidal joint injections, etc.)
✓. VAS score of 4 or higher and moderate-severe elbow or wrist pain

Exclusion criteria

✕. Those with a VAS Score of less than 4 and Mild Elbow or Wrist Pain
✕. Chronic Renal Insufficiency(Serum creatinine \> 2mg/dL)
✕. allergy to iodide contrast agents that do not respond to steroids
✕. Those with acute infection or malignancy
✕. Those who have previously had elbow or wrist surgery
✕. Those with Bleeding Diabetes that cannot be calibrated

What they're measuring

Rate of subjects with a 50% or more reduction in QuickDASH Score Change

Timeframe: 2~7days,1 month, 3 months, 6 months

Trial details

NCT IDNCT06207851

SponsorNext Biomedical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07-13

Contact for this trial

Sang Woo Park

+82-32-454-4800 next@nextbiomedical.co.kr

View on ClinicalTrials.gov More Osteoarthritis trials